^
    Back
    Association details:
    Biomarker:UGT1A1*28
    Cancer:Colorectal Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer

    Excerpt:
    ...RAS/BRAF mutation status and UGT1A1*28/*6 gene polymorphism typing should be determined before enrollment....
    Trial ID:
    NCT05969899
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

    Excerpt:
    ...- Genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/ UGT1A1*28...
    Trial ID:
    NCT00628810
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer

    Excerpt:
    ...- Homozygous for allele UGT1A1*28, the promoter of the gene coding for UGT1A1 (genotype 7/7)...
    Trial ID:
    NCT00541125
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients

    Excerpt:
    ...Patients who are eligible to be registered in the study, based upon the above criteria, will be genotyped for the UGT1A1*28 polymorphism and stratified into two groups based on the presence of the UGT1A1*1/*1 or UGT1A1*1/*28 genotype....
    Trial ID:
    NCT01183494
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur J Cancer
    Title:

    Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST)

    Published date:
    08/20/2020
    Excerpt:
    The control group received conventional biweekly FOLFIRI plus bevacizumab without UGT1A1 genotyping, whereas the study group received the same regimen with irinotecan dose escalation based on UGT1A1 genotyping….The median PFS was 14.0 and 10.0 months in the study and control group, respectively...our study provides evidence that higher-than-recommended doses of irinotecan might be safely implemented in the FOLFIRI regimen plus bevacizumab for mCRC patients with UGT1A1∗1/∗1 and UGT1A1∗1/∗28 genotypes...
    Secondary therapy:
    FOLFIRI
    DOI:
    https://doi.org/10.1016/j.ejca.2020.05.031
    Trial ID:
    NCT02256800